{"id":"imiquimod-5-cream-with-prior-curettage","safety":{"commonSideEffects":[{"rate":"60-90","effect":"Local skin irritation / erythema"},{"rate":"40-70","effect":"Pruritus"},{"rate":"20-50","effect":"Erosion / ulceration"},{"rate":"30-60","effect":"Scabbing / crusting"},{"rate":"5-15","effect":"Systemic flu-like symptoms"},{"rate":"5-10","effect":"Lymphadenopathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Imiquimod binds to TLR7 on immune cells, triggering production of interferon-alpha and other cytokines that activate dendritic cells and T cells. When applied topically after curettage (mechanical removal of lesion), it promotes local immune-mediated destruction of remaining tumor cells. This combination approach leverages both mechanical debulking and immunological clearance.","oneSentence":"Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to enhance local anti-tumor and anti-viral immunity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:45.336Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Basal cell carcinoma (superficial or nodular) following curettage"},{"name":"Actinic keratosis"},{"name":"Cutaneous squamous cell carcinoma in situ"}]},"trialDetails":[{"nctId":"NCT02242929","phase":"PHASE3","title":"Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma","status":"UNKNOWN","sponsor":"Maastricht University Medical Center","startDate":"2016-01","conditions":"Nodular Basal Cell Carcinoma","enrollment":145}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aldara"],"phase":"phase_3","status":"active","brandName":"Imiquimod 5% cream with prior curettage","genericName":"Imiquimod 5% cream with prior curettage","companyName":"Maastricht University Medical Center","companyId":"maastricht-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to enhance local anti-tumor and anti-viral immunity. Used for Basal cell carcinoma (superficial or nodular) following curettage, Actinic keratosis, Cutaneous squamous cell carcinoma in situ.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"1998-09-18T00:00:00.000Z","mah":"Viatris Healthcare Limited","brand_name_local":"Aldara","application_number":"EMEA/H/C/000179"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}